Phase I Study of TENPA in Advanced Solid Cancer

NCT02979392 | Terminated Phase 1

• 1 other identifier: H1604-140-758
• Study Type: interventional
• Target: 19
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to investigate the safety and to determine maximum tolerated dose and recommended phase 2 dose of TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) in patients with advanced solid tumor.

Conditions

Advanced Solid Tumor

Outcome Measures

Primary Outcomes (2)

• Dose limiting toxicity (DLT)

  at least one cycle of treatment (3 weeks)

• Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D)

  at least one cycle of treatment (3 weeks)

Secondary Outcomes (4)

• Maximum Plasma Concentration [Cmax]

  3 weeks

• Area Under the Curve [AUC]

  3 weeks

• Response rate (RR)

  6 weeks

• Progression-free survival (PFS)

  6 weeks

Study Arms (1)

Phase I

EXPERIMENTAL

Part A, Dose escalation TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) IV once every 3 weeks (Phase I starting dose 75 mg/m2) Part B, Expansion TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) IV once every 3 weeks (RP2D dose determined in part A)

Drug: TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel)

Interventions

TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) DRUG

TENPA IV once every 3 weeks (Phase I starting dose 75 mg/m2)

Phase I

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Willing and able to provide written informed consent for voluntary participation in the trial
• Twenty years of age or older on the day of signing informed consent
• Advanced solid tumors with no standard treatment available
• Evaluable disease or have measurable lesion
• ECOG performance score of 0 or 1
• Life expectancy ≥ 12 weeks
• Adequate organ and marrow function as defined below:
• A. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (\> 1500 per mm3) B. Haemoglobin ≥ 8.0 g/dL C. Platelet count ≥ 100 x 109/L (\>100,000 per mm3) D. AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional ULN E. Serum bilirubin ≤ 2 x institutional upper limit of normal (ULN) F. Serum creatinine ≤ 1.5 mg/dL
• Adequate heart function A. QT interval corrected for heart rate (QTc) ≤ 480 ms
• In the opinion of the investigator likely to have the willingness to comply with the study protocol during and after the study period and capable of complying with it
• Negative serum pregnancy test (β HCG) upon study entry and agree to use contraception

You may not qualify if:

• Uncontrolled CNS metastatic disease (radiographically unstable and symptomatic disease). (note) Subjects with previously treated CNS metastases (surgery or stereotactic brain radiation therapy) that are radiographically stable for at least 4 weeks are permitted to enroll. Subjects should not receive corticosteroids within 3 weeks prior to study enrollment.
• History of leptomeningeal carcinomatosis; brain metastasis with seizure not controlled with standard medical management.
• Major surgery within 4 weeks: patient must have recovered from any effects of any major surgery.
• History of hematopoietic stem cell transplantation or solid organ transplantation
• History of Gilbert's syndrome
• Prior malignancy except:
• Basal cell carcinoma and squamous cell carcinoma of the skin that has undergone potentially curative surgery, in situ cervical cancer that has undergone potentially curative surgery and had no evidence of recurrence at least in past 3 years, other malignancy that has undergone curative surgery and had no evidence of disease at least in past 5 years.
• Significant cardiovascular disease, such as: history of myocardial infarction, acute coronary syndrome or coronary angioplasty/stenting/bypass grafting within the last 6 months; History or current evidence of clinically significant arrhythmia or conduction disorder, except symptomatic congestive heart failure (CHR), atrial fibrillation, and paroxysmal supraventricular tachycardia (PSVT)
• Sustained uncontrolled hypertension
• Test results indicating active infection with human immunodeficiency virus (HIR) or hepatitis B or C, defined by positive serology testing (note) inactive hepatitis B carrier on antiviral agents are permitted to enroll.
• Neuromuscular disorder associated with CK elevation (eg. Inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, and spinobulbar muscular atrophy)
• Uncontrolled intercurrent illness or symptoms including, but not limited to, ongoing or active infection, bowel obstruction, psychiatric illness/social situations that would limit compliance with study requirement.
• Radiation therapy within 2 weeks of the first dose of study drug: patient must have recovered from any effects of radiation therapy
• Pregnant or breast feeding.
• Female subjects of childbearing potential within the projected duration of the study, starting with the screening visit through 30 days after the last dose of study drug.

Sponsors & Collaborators

• Yung-Jue Bang: lead

Study Sites (1)

Seoul National University Hospital

Seoul, 110-744, South Korea

Location

Study Officials

• Yung-Jue Bang

  Seoul National University Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: November 27, 2016
• First Posted: December 1, 2016
• Study Start: May 2, 2016
• Primary Completion: July 4, 2019
• Study Completion: July 4, 2019
• Last Updated: September 25, 2019

Record last verified: 2019-09

Locations

KR (1)